The State of AI in Drug Discovery 2024

In GEN’s inaugural summit, The State of AI in Drug Discovery, we proudly host an outstanding group of thought-leaders, researchers and AI entrepreneurs across industry and academia to showcase the latest advances, challenges and concerns regarding the deployment of AI in biotech, with particular emphasis on disrupting the drug discovery process. The post The State of AI in Drug Discovery 2024 appeared first on GEN - Genetic Engineering and Biotechnology News.

Artificial Intelligence (AI) and machine learning are transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. Leveraging the rise of large datasets and massive compute power, AI appears poised to expedite and, in some cases, reimagine the design of novel and more effective therapeutics, from cell and gene therapy, oncology, neuroscience, and more. In inaugural virtual summit, , we proudly host an outstanding group of thought-leaders, researchers and AI entrepreneurs across industry and academia to showcase the latest advances, challenges and concerns regarding the deployment of AI in biotech, with particular emphasis on disrupting the drug discovery process.

This exciting event brings together founders and executives from many of the most exciting companies powering the AI revolution, including Recursion, 1910 Genetics, Profluent, Terray Therapeutics, Generate:Biomedicines, and more! Please join us on October 30th for a dynamic program featuring: Registration for is entirely free..